Global Precision Cardiology Market
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
February 28, 2022 06:28 ET | Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
December 22, 2021 04:00 ET | AFFiRiS AG
前沿生物获得在大中华区开发与商业化AFFITOPE®AT04的独家权利合作旨在加快AFFITOPE®AT04主动免疫疗法作为同类首创新药的全球开发进程,推动其在大中华区的临床开发和生产落地 中国南京和奥地利维也纳, Dec. 22, 2021 (GLOBE NEWSWIRE) --...
AFFiRiS and Frontier
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
December 22, 2021 04:00 ET | AFFiRiS AG
Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class...
Esperion Logo (primary).png
ESPERION Announces Plan for Transformative Long-Term Growth
October 18, 2021 07:00 ET | Esperion Therapeutics, Inc.
–Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial– –Reduces overall workforce by 40...
AC Immune acquires A
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
July 27, 2021 08:00 ET | AFFiRiS AG
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further...
AFFiRiS: Positive ph
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
May 27, 2021 05:00 ET | AFFiRiS AG
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune responseAT04A treatment...
Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents
March 23, 2021 08:03 ET | Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to's offering. The report estimates that in 2018, there were...
Esperion Logo (primary).png
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
February 23, 2021 16:01 ET | Esperion Therapeutics, Inc.
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic...
Esperion Logo (primary).png
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15, 2020 07:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating...
Esperion Logo (primary).png
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
November 10, 2020 16:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal...